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Characteristically, enterohemorrhagic Escherichia coli (EHEC) strains produce Shiga-like toxin type I
(SLT-I), SLT-II, or both of these immunologically distinct cytotoxins. No antigenic or receptor-binding
variants of SLT-I have been identified, but a number of SLT-II-related toxins have been described. Because
EHEC 091:H21 strain B2F1, which produces two SLT-II-related toxins, is exquisitely virulent in an orally
infected, streptomycin-treated mouse model (oral 50% lethal dose [LD501, <10 organisms), we asked whether
the pathogenicity of strain B2F1 was a consequence of SLT-II-related toxin production. For this purpose, we
compared the lethality of orally administered E. coli DH5ct(Strr) strains that produced different cytotoxic levels
of SLT-II, SLT-Ilvha (cloned from B2F1), SLT-Ilvhb (also cloned from B2F1), or SLT-IIc (cloned from EHEC
0157:H7 strain E32511) on Vero cells. We also calculated the specific activities of purified SLT-Ilvhb and
SLT-II in intraperitoneally injected mice and on Vero cells. The two purified toxins were equally toxic for mice,
but SLT-Ilvhb was approximately 100-fold less active than SLT-II on Vero cells and bound to the glycolipid
receptor Gb3 with lower affinity than did SLT-II. In addition, characterization of SLT-II-related toxin-binding
(B) subunit mutants generated in this study revealed that the reduced in vitro cytotoxic levels of the
SLT-II-related toxins were due to Asn-16 in the B subunit. Taken together, these findings do not support the
idea that B2F1 is uniquely virulent because of the in vivo toxicity of SLT-II-related toxins but do demonstrate
differences in in vitro cytotoxic activity among the SLT-II group produced by human EHEC isolates.
Infection with enterohemorrhagic Escherichia coli (EHEC)
is associated with food-borne outbreaks of diarrhea (47),
hemorrhagic colitis (28, 41, 42), and the hemolytic uremic
syndrome (17, 24, 28, 39). One such outbreak occurred recently in the Pacific Northwest (3, 34). A key characteristic of
these EHEC strains is that they produce Shiga-like toxins
(SLTs) (for reviews, see references 10, 17, 33, 52, and 53).
These SLTs, also known as verotoxins (VT) (18), inhibit
protein synthesis by cleaving a specific adenine residue in the
28S subunit of eukaryotic rRNA (6). They are multisubunit
toxins that consist of one enzymatically active A subunit and
five receptor-binding B subunits and are cytotoxic for Vero
tissue culture cells (33).
Two groups of SLTs that differ significantly in immunological reactivity have been described. They have been designated
Shiga-like toxin type I (SLT-I) and Shiga-like toxin type II
(SLT-II). The SLT-I group contains the prototype toxin SLT-1
in addition to Shiga toxin from Shigella dysenteriae type I.
SLT-I and Shiga toxin differ by only one amino acid (49) and
are considered to be the same toxin. SLT-I/Shiga toxin uses the
glycolipid globotriaosylceramide (Gb3; Galotl-4 Galrl4Glc,B1-lCer) as the functional eukaryotic cell surface receptor

anti-SLT-I/Shiga toxin monoclonal or polyclonal antiserum
(15). Unlike the SLT-I/Shiga toxin group, the SLT-II group
exhibits sequence and antigenic variation. SLT-II produced by
EHEC 0157:H7 strains is considered the prototype toxin for
this group, which also includes the toxin responsible for edema
disease of swine (25, 29, 58), SLT-IIv (recently renamed
SLT-IIe [see Materials and Methods for discussion of nomenclature]). In contrast to SLT-II, SLT-IIv binds more avidly to
globotetraosylceramide (Gb4; GalNAcI1-3Galo 1-4Gal,B 14GlcP1-1Cer) than to Gb3 (4, 43).
Since 1990, a number of new SLTs have been identified that
are considered members of the SLT-II group on the basis of
sequence homology and immunological cross-reactivity with
SLT-II. These SLT-II group members include SLT-Ilvha
(VT2vha), SLT-Ilvhb (VT2vhb), and SLT-IIc, all of which are
nearly 97% homologous to SLT-1I at the deduced amino acid
sequence level (14, 45). Other SLT-II-related toxins have been
described (8, 12, 21, 30, 37, 44, 54, 59), but many of these toxins
were detected by PCR analysis and only a few have been
isolated and sequenced.
Several clinical EHEC isolates that contain more than one
copy of slt-II have been reported. Schmitt et al. described five
such strains (45), including E. coli 0157:H- strain E32511,
which contains slt-II and slt-IIc, and E. coli 091:H21 strain
B2F1, which contains slt-Ilvha and slt-Ilvhb (14). We recently
cloned and characterized three genes for SLTs from the EHEC
091:H21 isolate H414-36/89 (21). Antigenic analysis showed
that two of the toxins from EHEC H414-36/89 were SLT-II
related and that one was similar to the prototype SLT-I1 toxin.
A number of epidemiological studies have correlated infection with EHEC strains that produce high levels of SLT and

(20, 23).

The members of the SLT-II group cannot be neutralized by
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TABLE 1. Bacterial strains and plasmids used or discussed in this study
Description or genotype

Strain or plasmid

E. coli strains
DH5ot
CJ236
B2F1
H414-36/89
E32511

Plasmids
pCKS120
pCKS123
pCKS184
pCKS188
pCKS189
pJES120
pSQ12
pSQ343
pJES54

pSQ543
pSQ545
pSJ5431

pSJ5432
pSJ5433
pSQ549
pSJ5491
pSJ5492
pSJ5493

Source or reference

supE44 AIacUJ69 (4801acZAM15)hsdRI7 recAl endAl gyrA thi-l relAl
dut-J ung-J thi-J relA1(pCJ105)
091:H21 EHEC isolate; slt-Ilvha, slt-Ilvhb
091:H21 EHEC isolate; two slt-II-related toxins, one slt-II
0157:H7 EHEC isolate; slt-1I, slt-Ilc

11
19
14
21
45

5.5-kb EcoRI slt-IIc fragment from E32511 in pBR328
4.8-kb EcoRI slt-II fragment from E32511 in pBR328
1.8-kb slt-IIc fragment from E32511 in pBR328
pCKS184 with B subunit mutation N16D
pCKS184 with B subunit mutation A24D
slt-1I in pSK(-)
slt-IIvha from B2F1 in pHC79
slt-lIvha in pKS(-)
slt-Ilvhb from B2F1 in pHC79
2.8-kb Pstl-EcoRI slt-Ilvhb fragment from pJES54 in pSK(-)
2.8-kb Pstl-EcoRI slt-Ilvhb fragment in pKS(-)
pSQ543 with B subunit mutation N16D
pSQ543 with B subunit mutation A24D
pSQ543 with B subunit double mutation N16DA24D
2.8-kb BamHI-HindIII slt-Ilvhb fragment from pSQ543 in pBR328
2.8-kb BamHI-HindIII s1t-IIvhb/N16D fragment from pSJ5431 in pBR328
2.8-kb BamHI-HindTII slt-Ilvhb/A24D fragment from pSJ5432 in pBR328
2.8-kb BamHI-HindIII slt-IIvhb/N16DA24D fragment from pSJ5433 in pBR328

This study
This study
This study
This study
This study
21
21
21
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

the development of the hemolytic uremic syndrome (17, 24, 28,
39). Some of these investigators have incriminated the SLT-II
group more than the SLT-L group in the development of
microangiopathic sequelae. Specifically, epidemiological data
from both Seattle (36) and England (46) indicate that strains
that produce SLT-II alone are more likely to cause hemorrhagic colitis that results in the hemolytic uremic syndrome or
thrombotic thrombocytopenic purpura than are strains that
produce SLT-I and SLT-II or those that produce SLT-I alone.
Furthermore, animal model EHEC studies by Wadolkowski et
al. (57), Barrett et al. (1), and Francis et al. (7) have shown a
similar correlation between SLT-II production and severity of
disease in mice, rabbits, and gnotobiotic piglets, respectively.
Recently, we reported that the EHEC 091:H21 strains B2F1
and H414-36/89 isolated from patients with the hemolytic
uremic syndrome and hemorrhagic colitis, respectively, were
highly virulent (50% lethal dose [LD50], less than 10 organisms) in an orally inoculated, streptomycin-treated mouse
model (21). We also found that EHEC strains that contain
slt-II alone or slt-IT in conjunction with only one slt-TI-related
toxin gene or with one slt-I gene are significantly less virulent
in the same model system (21). The aim of the present
investigation was to determine whether differences in toxicity
between SLT-TI and SLT-II-related toxins might explain the
exquisite virulence of EHEC B2F1 in orally challenged mice.
To test this hypothesis, the effects of the toxins were compared
after delivery of toxin by E. coli DH5t(Strr) in the orally
infected mouse model and after purification and injection
intraperitoneally into mice.
(A portion of this work was presented at the 92nd General
Meeting of the American Society for Microbiology, New
Orleans, La., 26 to 30 May 1992 [22].)
MATERIALS AND METHODS

Bacterial strains and plasmids. The bacterial strains and
recombinant plasmids used or discussed in this study are listed

in Table 1. Table 2 describes the amino acid relationship
among relevant SLT-II-related toxins used. The new nomenclature for SLT-II-related toxins that appear to be closely
related to SLT-II by DNA hybridization and sequence homology and exhibit only minor variations in other properties is
"SLT-IIc," and the name for the toxin produced by E. coli that
causes edema disease in swine has been changed from SLT-IIv
to SLT-Ile (58a). However, the original designations for the
"SLT-IIc" toxins, SLT-IIvha, SLT-Ilvhb, and SLT-IIc, will be
retained in this study so as to precisely identify the particular
clones and toxin sequences. Collectively, these toxins will be
called SLT-II-related toxins.
Media, enzymes, and biochemicals. Bacterial strains were
routinely grown in Luria-Bertani medium (27). When selective
pressure was required, the medium was supplemented with
antibiotics (Sigma Chemical Co., St. Louis, Mo.) at the following concentrations per milliliter: ampicillin, 200 jg for pBluescript vectors and 100 ,ug for pBR328 and pHC79; streptomycin, 30 ,ug. Restriction enzymes, RNase, Klenow DNA
polymerase, and T4 DNA ligase were purchased from Boehringer Mannheim Biochemicals, Indianapolis, Ind. Sequenase
TABLE 2. Amino acid sequence differences among SLT-II toxins'
Amino acid sequence of:

Toxin

B subunit

A subunit

SLT-II
SLT-IIc
SLT-Ilvha
SLT-Ilvhb

S19, H45, V252, F291, K297
*
S291, E297
T19, P45,
* P45, M252, S291, E297
*

*

*
*

*

D16, D24
N16, A24
N16, A24
N16, A24

a Amino acids at the positions listed in the processed A subunit (297 total
amino acids) or B subunit (70 total amino acids) of SLT-II (15), SLT-IIc (45),
SLT-Ilvha (14), and SLT-Ilvhb (14).
b S, serine; H, histidine; V, valine; F, phenylalanine; K, lysine; D, aspartate; T,
tyrosine; P, proline; E, glutamine; M, methionine; *, amino acid identity with the
prototype SLT-II toxin at that position.
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enzyme and Sequenase sequencing kits were purchased from
U.S. Biochemical Corp., Cleveland, Ohio. Silver grade fetal
calf serum was purchased from ICN Biomedical Inc., Irvine,
Calif., and Eagle's minimum essential medium was purchased
from Whittaker Bioproducts, Inc., Walkersville, Md.
Mouse feeding and LD50 studies. The method for mouse
feeding was described previously (56). CD-1 male mice aged 5
to 6 weeks old (Charles River Laboratories, Wilmington,
Mass.) were used throughout this study. Throughout each
experiment, mice were given drinking water which contained
streptomycin (5 g/liter) and ampicillin (5 g/liter). Oral streptomycin treatment reduces the level of facultative anaerobic
bacteria that normally colonize the mouse intestine (31). The
ampicillin was given orally to prevent segregation of plasmids
that contained ampicillin resistance markers. A spontaneously
streptomycin-resistant (Strr) E. coli K-12 strain [DH5co(Strr)]
transformed with vector alone or with vector containing a
cloned toxin gene was fed to groups of three to five mice at
levels of approximately 101' CFU. Mouse death was monitored
daily for 14 days. Kidneys were isolated from moribund mice or
healthy controls for histological analysis. The specimens were
fixed in 10% buffered formalin, processed routinely for histologic examination, and stained with hematoxylin and eosin.
The quantity of purified toxin required to kill mice was
assessed by LD50 studies. Various dilutions of purified SLT-II
or SLT-Ilvhb in 0.2 ml of sterile nonpyrogenic 0.9% saline
(Kendall McGaw Laboratories, Inc., Irvine, Calif.) were administered intraperitoneally to groups of five CD-1 mice. Deaths
were monitored daily, and LD50S were determined by the
method of Reed and Muench (40). The experiments reported
here were conducted according to the principles set forth in the
Guide for the Care and Use of Laboratory Animals (32).
Toxin purification. Both SLT-II and SLT-Ilvhb were purified from E. coli DH5ot that contained the appropriate toxin
gene on a high-copy pBluescript plasmid (Stratagene). Saturated overnight cultures of E. coli DH5ot/pJES120 (SLT-II) or
E. coli DH5ox/pSQ543 (SLT-Ilvhb) were inoculated into a total
of 6 liters of enriched medium (2% tryptone, 1% yeast extract,
0.5% NaCl, 0.2% glycerol). The bacteria were cultured for 24
h, harvested by centrifugation, and lysed by sonic disruption.
The bacterial lysates were clarified by centrifugation and
concentrated with 60% ammonium sulfate. The resultant
crude toxin preparations were dialyzed against 0.05 M Tris (pH
7.0) (SLT-II) or 0.05 M Tris (pH 8.0) (SLT-Ilvhb), subjected to
CL-6B DEAE-Sepharose anion-exchange chromatography
(Pharmacia, Uppsala, Sweden) with the same buffer, and
eluted with a 0 to 1.0 M NaCl gradient. The cytotoxic fractions
were pooled and dialyzed against chromatofocusing starting
buffer (for SLT-II, 0.025 M histidine-HCl [pH 6.2]; for SLTIlvhb, 0.025 M imidazole-HCl [pH 7.4]). The toxin preparations were then applied to a chromatofocusing column (Polybuffer-exchanger 94 [Pharmacia]) that had been equilibrated
with the appropriate starting buffer. Fractions were eluted
from the column with Polybuffer 74-HCl (pH 4.0) (Pharmacia).
The cytotoxic fractions were pooled and dialyzed against
phosphate-buffered saline (PBS) and then subjected to immunoaffinity chromatography with monoclonal anti-SLT-II B
subunit antibody (designated BC5BB12, kindly supplied by N.
Strockbine, Centers for Disease Control, Atlanta, Ga. [5]) as
the adsorbent. Fractions were eluted from the immunoaffinity
column with 0.1 M glycine (pH 2.8) and immediately neutralized with 50 .1I of I M Tris (pH 9.0). The cytotoxic activity and
the homogeneity of each fraction were assessed by Vero cell
cytotoxicity and denaturing polyacrylamide gel electrophoresis,
respectively. The fraction(s) that contained the highly purified
toxin protein was dialyzed against PBS and stored at 4°C.

Purified toxin protein concentrations were determined in
triplicate with a Micro-BCA protein assay reagent kit (Pierce).
Cytotoxicity and toxin immunoreactivity assay. Cytotoxicity
assays of bacterial cell lysates and purified toxin preparations
were done with Vero cells by the method of Gentry and
Dalrymple (9). The 50% Vero cell cytotoxic dose (CD511) is
expressed per milliliter of culture and is the reciprocal of the
highest dilution of toxin that caused 50% Vero cell death.
Toxin immunoreactivity assays were done by incubating a
single dilution of antibody with serial twofold dilutions of
clarified bacterial cell lysates for 4 h at 37°C. The toxinantibody mixture was then placed on Vero cells and incubated
for an additional 48 h. The cells were then fixed in formalin
and stained with crystal violet, and the A6,20 was measured in a
Titertek Multiskan MC microplate reader (Flow/ICN Biomedicals, Costa Mesa, Calif.) to assess cell death. The antibodies used for cytotoxin immunoreactivity experiments included polyclonal anti-SLT-II (designated AJ65 [50]), ascitic
fluid of monoclonal anti-SLT-II B subunit (designated
BCSBB512, [5]), and culture fluid of monoclonal anti-SLT-II A
subunit (designated 2El [38]).
Quantification of toxin protein from crude toxin preparations. A comparative immuno-dot blot analysis was used to
determine the amount of SLT protein present in various crude
toxin preparations. Serial dilutions of either sonically disrupted
bacterial cultures or purified toxin preparations were spotted
onto BAS-NC nitrocellulose (Schleicher & Schuell, Inc.,
Keene, N.H.) through a 96-well dot blot apparatus (Schleicher
& Schuell) connected to a vacuum. The nitrocellulose membrane was air dried and incubated for I h at room temperature
in PBS-0.1% Tween 20 (Bio-Rad Laboratories, Richmond,
Calif.) (PBS-T) which contained 5% nonfat dried milk (Carnation Co., Los Angeles, Calif.). The membrane was washed
with PBS-T and then incubated with a 1:5 dilution of antiSLT-II A subunit monoclonal antibody (designated 1 IEIO
[38]) in PBS-T for 1 h. The membrane was washed three times
with PBS-T to remove unbound antibody and then incubated
for 1 h with a 1:500 dilution of horseradish peroxidaseconjugated goat anti-mouse immunoglobin G antibody (BioRad) in PBS-T. After incubation, the membrane was washed
five times in PBS-T, immersed in ECL Western immunoblotting detection reagent (Amersham International, Amersham,
United Kingdom) for 1 min, and then immediately exposed to
X-Omat film (Eastman Kodak Co., Rochester, N.Y.) for 15 s
to 3 min.
Recombinant DNA techniques. Plasmid DNA was purified
by alkali lysis (2) or by Qiagen column preparation (Qiagen
Inc., Chatsworth, Calif.). DNA fragments used for subcloning
were separated by agarose gel electrophoresis (0.9% agarose)
and eluted from the gel matrix with the GeneClean system
(Bio 101, La Jolla, Calif.). Ligated fragments were transformed
into E. coli K-12 strains made competent for uptake of DNA by
calcium chloride treatment and heat shock (26).
Site-directed mutagenesis of slt-Ilvhb and slt-IIc B subunits.
Two oligonucleotides designed to introduce point mutations
were synthesized on the basis of the sequence for slt-Ilvhb (14)
and slt-Ilc (45) with a model 380A DNA synthesizer (Applied
Biosystems, Inc., Foster City, Calif.). Oligonucleotide N16D, G
TAT AAT GAG GAT GAT ACA TTC, altered codon 16 of
the mature B subunit of slt-Ilvhb and slt-IIc from AAT to GAT
of slt-II. Oligonucleotide A24D, GTA AAA GTG GAC GGA
AAA GAG, altered codon 24 of the mature B subunit of
slt-Ilvhb and slt-Ilc from GCC to GAC of slt-II. Uracilincorporated, single-stranded pSQ543 or pCKS184 DNA was
mutagenized according to the directions supplied with the
Bio-Rad Muta-Gene in vitro mutagenesis kit. The double
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TABLE 3. Virulence in orally inoculated mice of E. coli
DH5ot(Strr) that produce SLT-II-related toxins
Plasmid

Cytotoxicity
CD5(/ml of

(no. dead/no, fed)

IIc

1 x 104
1 x 106
1 x 103

23/23
9/10

Ilvha
IIvhb
Ilvhb
II
II

5 x 102
5 x 104
1 x 102
1 x 107
1 x 105

10/10
9/9
1/10
5/5
0/10

102
102
102

0/10
0/10
0/10

Toxin

(Vero

culture)'

Expt 1
pSQ343
pSQ543
pCKS120

Expt 2
pSQ12

pSQ545
pSQ549
pJES120
pCKS123

Controls
pKS(-)
pHC79
pBR328

IIvha
Ilvhb

None
None
None

<1 x
<1 x
<1 x

Mouse death6

10/10

a Cytotoxicity values were determined on the cultures that were fed to the
mice. The lowest level of detection for this assay was 102 CD50/ml.
6 Mice were fed approximately 10'0 CFU bacteria and monitored for death for
14 days. Each ratio represents pooled data from one to six experiments.

mutant SLT-Ilvhb/N16DA24D was generated with the single
mutant SLT-Ilvhb/N16D as the template and the A24D oligonucleotide as the mutagenic primer. All of the nucleotide
changes used to generate the B subunit mutations were
confirmed by DNA sequence analysis.
Toxin-receptor affinity analysis. The affinities of SLT-II and
SLT-Ilvhb for Gb3 were determined by an in vitro binding
assay done as previously described (43) except that purified
Gb3 and purified SLTs were used instead of crude preparations
of these reagents.

RESULTS
Virulence of E. coli DH5a producing SLT-II-related toxins
in streptomycin-treated, orally infected mice. Recent studies in
our laboratory demonstrated that both EHEC 091:H21 strains
B2F1 and H414-36/89 have LD50s of less than 10 bacteria in
orally infected, streptomycin-treated mice (21). Both of these
091:H21 strains contain two copies of slt-TI-related toxin
operons (14, 21). Furthermore, passive immunization of mice
with anti-SLT-II antibody prior to oral inoculation with B2F1
or H414-36/89 protects mice from death (21). These data

indicate that production of SLT-II-related toxins is critical for
the virulence of these strains in mice. To determine whether
production of SLT-II-related toxin by an E. coli K-12 strain was
sufficient to cause the death of orally infected mice, ampicillinresistant plasmids that contained slt-IIvha, slt-Ilvhb, or slt-IIc
were separately transformed into E. coli DH5ot(Strr) and fed to
mice treated with streptomycin and ampicillin. Production of
the SLT-II-related toxins by E. coli DH5a(Strr) was lethal for
the orally inoculated mice (Table 3, experiment 1). Moreover,
mice that were fed E. coli DH5ca(Strr) that elaborated SLT-IIrelated toxin developed renal lesions similar to those found in
mice that were fed the 091:H21 strains (Fig. 1) (21). These
data support the hypothesis that the elaboration of SLT-ITrelated toxin even by a laboratory-attenuated E. coli K-12
strain is sufficient to cause renal lesions and death of orally
inoculated mice. None of the control mice fed E. coli
DH5o(Strr) transformed with vector alone died (Table 3).

Previous studies by Wadolkowski et al. (56) demonstrated
that E. coli DH5ox(Strr) that contained cloned slt-IT toxin
operons also caused kidney lesions, but levels of at least 106
Vero CD50 SLT-TT per ml were required for these recombinant
strains to be lethal in the orally inoculated mice. To assess the
relative oral toxicity of the nearly homologous (Table 2)
SLT-IT-related toxins in mice, E. coli DH5ot(Strr) strains that
produced lower levels of these toxins, as determined by Vero
cell cytotoxicity, were fed to streptomycin-treated mice (Table
3, experiment 2). These toxin-producing E. coli DH5ox(Strr)
strains were constructed by cloning the slt-Ilvha and slt-Ilvhb
toxin operons into lower-copy-number vectors or into pBluescript vectors in the reverse orientation of the P10C promoter
(Table 1). Results from this set of feeding experiments demonstrated that E. coli DH5ot(Strr) strains that produced SLTIT-related toxins at Vero cell cytotoxicity titers of 5 x 102 to 1
x 103 Vero CD50/ml remained lethal in mice (pSQ12,
pCKS120 [Table 3]). The toxin-expressing strains had an
apparent threshold of lethality at Vero cell cytotoxicity levels
of approximately 102 (pSQ549 [Table 3]). By contrast, E. coli
DH5ot(Strr) strains that made SLT-I1 were consistently lethal
only when the Vero CD50 per milliliter produced were 107
(pJES120 [Table 3]).
Specific activity of purified SLT-Ilvhb on Vero cells and in
mice given intraperitoneal injections. One explanation for the
observation that E. coli DH5ot(Strr) transformants that produce 102 to 103 Vero CD50 of SLT-IIvha, SLT-Ilvhb, or
SLT-IIc per ml kill orally inoculated mice, whereas E. coli
DH5oa(Strr) transformants that make as much as 105 Vero
CD50 of SLT-IT per ml fail to do so, is that the toxins differ in
specific activity at the in vitro or in vivo level, or both. To test
this hypothesis, SLT-Ilvhb and SLT-T1 were purified and the
specific activities of the toxins were compared on Vero cells
and in CD-1 mice. SLT-Ilvhb was selected for purification
because SLT-ITvha, SLT-IIvhb, and SLT-IIc have identical B
subunit sequences and a clone of slt-TTvhb that produced high
levels of toxin was available. The in vitro specific activity of
SLT-II on Vero cells was approximately 5 pg/CD50, a value
comparable to published results (60). However, the Vero cell
specific activity of purified SLT-Ilvhb was about 100-fold lower
than that of SLT-TI (approximately 500 pg/CD50 for three
SLT-IIvhb toxin preparations). When the purified toxins were
intraperitoneally injected into CD-1 mice, SLT-11 and SLTITvhb were equally toxic. The in vivo specific activity of both
SLT-II and SLT-Ilvhb was 1 to 2 ng/LD501. Thus, SLT-I1 was
more toxic for Vero cells than SLT-Ilvhb was, but the toxins
were equally toxic in mice. Therefore, the apparent difference
in the in vivo toxicity of E. coli DH5oL(Strr) transformants that
produce SLT-TI-related toxins versus SLT-II reflects the use of
Vero CD50 as a measure of activity.
Comparison of the ratio of Vero cell active toxin (as
measured by CD50) to total toxin (as measured by immunoreactivity) in crude preparations of SLT-II-related and SLT-II
toxins. One explanation for the lower specific activity of
SLT-II-related toxins on Vero cells is that the ratio of Vero cell
active toxin to Vero cell inactive toxin is lower for the
SLT-II-related toxins. A two-step experimental approach was
used to test this hypothesis. First, the amount of toxin antigen
per unit protein in crude extracts of SLT-1I-related and SLT-II
toxins was compared by immunoblot analysis with a monoclonal antibody specific for the A subunit of SLT-TT. This monoclonal antibody was chosen as a probe because minor amino
acid changes in the A subunit of SLTs appear to cause little or
no variation in the reactivity of the toxins with antibodies (13).
As a control, the immunoreactivities of purified SLT-II and
purified SLT-Ilvhb were compared and found to be similar.
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FIG. 1. (A) Photomicrograph of the renal cortex from a normal CD-1 mouse. No lesions were evident in the renal cortex of this or other control
animals. (B) Photomicrograph of the renal cortex from a moribund, streptomycin-treated CD-1 mouse fed approximately 10" CFU of E. coli
DH5a(Strr)/pSQ543 (expresses SLT-Ilvhb). The moribund mouse was sacrificed on day 3 postinoculation, and the tissue was prepared as described
in Materials and Methods. The lumens of several of the tubules were dilated and contained necrotic tubular epithelial cells. The dilated tubules
(dt) were lined with fewer, more flattened, tubular epithelial cells than were the lumens of unaffected tubules (ut) as a result of loss of the adjacent
cells. The glomeruli (g) appeared histologically normal. This photomicrograph is representative of renal sections obtained from several mice
infected with E. coli DH5aL that expresses SLT-II-related toxin. For both panels, hematoxylin and eosin stained; magnification, x 200.

This latter observation supports our supposition that the two
toxins react equally well with this monoclonal antibody (Fig. 2)
in the immunoblot assay. The crude toxin preparations from E.
coli DH5at that expressed SLT-II(pJES120), SLT-Ilvha-

(pSQ343), or SLT-Ilvhb(pSQ543) and produced 1 x 107, 5 x
104, and 5 x 105 Vero CD5(/ml, respectively, appeared to
contain similar amounts (within a twofold difference) of toxin
antigen (Fig. 2). Thus, comparable amounts of toxin protein

628

LINDGREN ET AL.

INFECT. IMMUN.

SLT-II

SLT-IlIvhb

~~pSQ543
~~~~

pSQ343
FIG.

2.

Immunoblot

of crude toxin

quantitation of
purified SLT-11,
of a 10-fold dilution of sonically
SLT-IIvhb, and SLT-1 and 100
derived lysates of E. coli DH5ot/pJES120 (SLT-II), E. coli DH5ot/
p50543 (SLT-Ilvhb), or E. coli DH5at/pSQ343 (SLT-Ilvha) were
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The intensities of the dot-blot color reactions
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ratio),

since high levels of inactive toxin would titrate the neutralizing
antibody and result in low ratio. As demonstrated in Table 4,
a

the

cytotoxic

activity

SLT-1I

higher

for

assays

summarized

antibody

the

to

(CD50) per antigen unit

than for

in Table 4,

SLT-1I

SLT-II. These antibodies

cytotoxicity

SLT-IIvhb
we

B subunit
were

or

used
or

selected

was

significantly
For the

SLT-IIc.

either monoclonal

polyclonal antisera to
because they neutralize

effectively than do anti-SLT-1I A subunit
monoclonal antibodies (45). Nonetheless, the
unit ratios were also significantly higher for SLT-II than for the
SLT-1i-related toxin preparations when the
more

CD5orantigen

immunoreactivity

assays were done with monoclonal antibody to the SLT-II A
subunit (data not shown). Together, the results described in
this section indicate that per microgram of toxin protein
SLT-II is more Vero cell active than are SLT-II-related toxins.
One caveat to this conclusion is that the SLT-II-related toxins
may not react as well in this type of immunoreactivity assay
with any antisera elicited against SLT-LI.
Identification of amino acids in the SLT-Ilvhb and SLT-IIc
B subunits responsible for reduced Vero cell activity. As
illustrated in Table 2, there are four amino acid differences
between SLT-II and SLT-Ilvha/SLTvhb in the A subunit and
two amino acid differences in the processed B or receptorbinding subunit (14). However, SLT-IIc, which has the same in
vitro phenotype as SLT-Ilvha/SLT-IIvhb, is identical to SLT-II
in the A subunit and to SLT-Ilvha/SLT-Ilvhb in the processed
B subunit (45). To determine whether one or both of the
amino acid differences in the B subunit of these toxins is
integral to the differential cytotoxic phenotype of the SLT-IIrelated toxins, we created two single and one double amino
acid substitution(s) in SLT-Ilvhb and two single mutations in
SLT-IIc. These mutations, SLT-IIvhb/N16D, SLT-IIvhb/
A24D, SLT-IIvhb/N16DA24D, SLT-IIc/N16D, and SLT-IIc/
A24D, were designed to make the toxins more like SLT-II at
the amino acid level and therefore correspond to the amino
acid codons present in the mature B subunit of SLT-LI at those
positions. Toxin preparations from E. coli DH5ot transformed
with the B subunit mutants cloned into pBR328 were subjected
to cytotoxicity and immunoreactivity analysis (Table 4). The
N16D mutation in both SLT-Ilvhb and SLT-IIc resulted in a
200-fold increase in cytotoxicity, whereas the A24D mutation
had little or no effect on SLT-II-related toxin cytotoxicity
levels. Similarly, the N16D mutation but not the A24D mutation altered the cytotoxin immunoreactivity profile of the
SLT-II-related toxins. The CD50/antigen unit ratios (the ratio
of cytotoxicity to cytotoxicity after incubation with antisera)
were low for the A24D mutants and the parent SLT-II-related
toxins but much higher for the N16D mutants, the SLT-Ilvhb/
N16DA24D mutant, and the prototype SLT-II toxin. The
absolute values for the ratios depended on the specificity of the
antiserum and the arbitrarily chosen standardized dose for that
antiserum. Preliminary mouse-feeding experiments were undertaken with strains expressing the mutant toxins; however,
these experiments were terminated after we found that SLTIlvhb and SLT-II have the same specific activity in vivo (see

TABLE 4. Specific toxicity of SLT-Ilvhb and SLT-IIc B subunit mutant toxin preparations
Anti-SLT-IIb
Toxin'

SLT-II

SLT-Ilvhb

SLT-Ilvhb/N16D
SLT-Ilvhb/A24D
SLT-IIvhb/N16DA24D
SLT-IIc
SLT-IIc/N16D
SLT-IIc/A24D

Toxicity
(CDRT Ml)
6.6
6.4
1.6
5.2
1.6
5
9.8
2.6

x 105
x 102
X 105
x 103

x 105
x 103

x 105
x 103

Antigen

units/mld

1.3
1.6
1.6
6.4
3.2
3.2
9.6
1.6

x 103
x 102
x 102
X 102
x 102
x 102

x 102
x 102

Anti-SLT-II B'

CD5(/antigen
unit'

512
5

1,000
8
500
16
1,024
16

Antigen

units/mld

4.8
4.2
4
1.3
1.6
5.1
3.2
3.2

x 102
x 102
x

101

x 103
x 102
X

103

102
x 102
x

CD59/antigen
unite

1,365
2
4,000
1
1,000
1
3,072
8

a Toxin preparations were from DH5cs transformed with pBR328-derived plasmids pSQ549 (SLT-Ilvhb), pSJ5491 (SLT-IIvhb/N16D), pSJ5492 (SLT-Ilvhb/A24D),
pSJ5493
(SLT-IIvhb/N16DA24D), pCKS120 (SLT-II), pCKS184 (SLT-IIc), pCKS188 (SLT-IIc/N16D), and pCKS189 (SLT-IIc/A24D).
b
AJ65, 1:25 dilution.
BC5 ascites, 1:100 or 1:200 dilution.
d
Antigen units/ml, CD1(1 of toxin antigen per milliliter that remains after incubation with antibody.
CD5(/antigen unit, CD0s( of a toxin preparation per milliliter divided by the CD50 of toxin antigen units of the homologous toxin preparation per milliliter. Units
given are arbitrary. Absolute values vary depending on the antibody used and cannot be compared between heterologous antibodies.
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FIG. 3. Receptor-binding affinities of SLT-II and SLT-Ilvhb. Saturating concentrations of purified toxin were incubated with serial
dilutions of purified Gb3. Receptor-bound toxin was detected by
incubation with saturating amounts of monoclonal antibody directed
against the SLT-II A subunit (designated l1E10 [38]) and '25I-labeled
sheep anti-mouse secondary antibody. Binding is expressed as counts
of '25I-labeled secondary antibody per minute. The receptor affinity
assay was done four times. Data shown are from a single representative
experiment. Symbols: 0, SLT-II; O, SLT-Ilvhb. Similar results were
obtained when a bovine anti-SLT-I1 antibody was used to detect the
Gb3-bound toxin (not depicted).

above). Taken together, the cytotoxicity and immunoreactivity
data indicate that the asparagine residue at position 16 is a
critical determinant of the SLT-II-related cytotoxin phenotype.
Binding affinity of purified SLT-Ilvhb and SLT-II to Gb3. A
possible reason for the reduced specific activity (picograms of
pure toxin per CD50) of SLT-II-related versus SLT-II toxins is
that the SLT-II-related toxins may bind with different affinities
to the putative functional receptor Gb3. Indeed, we previously
demonstrated that crude preparations of SLT-Ilvhb bind to
Gb3 receptor analogs but with less affinity than SLT-II does
(43). Purified SLT-II and SLT-Ilvhb used in the current study
were compared for relative affinity to Gb3 with a saturating
amount of toxin. The concentration of Gb3 required for
half-maximal binding of SLT-II was approximately 0.01 pLg of
Gb3 per well, whereas the Gb3 concentration for half-maximal
binding of SLT-Ilvhb was approximately 0.05 pg of Gb3 per
well (Fig. 3). Thus, SLT-II had a fivefold-higher affinity for Gb3
in this assay system.
DISCUSSION
Three principal conclusions were inferred from this study of
SLT-II and SLT-II-related toxins produced by EHEC. First,
the synthesis of these toxins by an avirulent, laboratory-derived
E. coli K- 12 strain was sufficient to cause kidney damage in and
kill orally infected, streptomycin-treated mice. Thus, toxin
alone is the key determinant of EHEC pathogenicity in this
mouse model. Second, the type of SLT-II produced by an
EHEC strain does not appear to affect the mouse virulence of
the strain because SLT-II and SLT-II-related toxins when
purified and injected parenterally into mice had comparable in
vivo specific activities. This conclusion does not rule out the

629

possibility that more SLT-II-related toxin than SLT-II is
produced in vivo by wild-type EHEC. Third, more SLT-IIrelated toxin antigen than SLT-II toxin antigen is required to
produce I CD50 on Vero cells. This lower specific cytotoxic
activity of SLT-II-related toxin on Vero cells reflects the amino
acid at position 16 of the B subunit and may be a consequence
of the lower affinity of binding to Gb3 on Vero cells.
Our observation that purified SLT-Ilvhb had a lower specific
cytotoxic activity on Vero cells than did the prototype SLT-II
toxin differs from the findings reported by Takeda and colleagues (35). These investigators found that toxin purified from
strain B2F1 (presumably a mixture of SLT-Ilvha and SLTIlvhb) has a Vero cell specific activity of 5.9 pg/CD50 (35), a
value that is similar to the specific activity of their preparation
of SLT-II (60), whereas we found the specific activity of
SLT-Ilvhb to be approximately 500 pg/CD50. The discrepancy
between our findings and those of Oku et al. (35) may reflect
differences in the Vero cell lines used in the two laboratories.
Despite these differences in cytotoxicity results, it should be
emphasized that the in vivo specific activity of the toxin
preparation purified from strain B2F1 by Oku et al. (35) (2.7
ng/LD50) is comparable to that obtained for SLT-Ilvhb in this
study (1 to 2 ng/LD50).
The finding that Asn-16 in the SLT-Ilvhb and SLT-IIc B
subunits was responsible for the reduction in cytotoxicity and
altered immunoreactivity of the SLT-II-related toxins on Vero
cells when compared with SLT-II suggests that Asn-16 is
involved in carbohydrate binding. That A subunit differences
between SLT-II and the SLT-II-related toxins are not important for the cytotoxicity and immunoreactivity profiles is indicated by the fact that SLT-IIc is identical to SLT-II in the A
subunit (Table 2) but has the same cytotoxicity and immunoreactivity profile as SLT-Ilvha/SLT-Ilvhb (Table 4). We also
found that mutant SLT-IIc/N16D is phenotypically similar to
SLT-Ilvhb/NI6D. Therefore, the only difference observed
between SLT-Ilvha/SLT-Ilvhb/SLT-IIc and SLT-II that is relevant to cytotoxicity appears to be the Asn-16 residue in the B
subunit. We are currently purifying the mutant toxins for
further receptor-binding analysis.
Additional lines of evidence in support of the importance of
the amino acid at position 16 in SLT toxin binding to receptors
are the site-directed mutagenesis studies of Jackson et al. (16)
and the X-ray crystallographic results of Stein et al. (48). Both
studies indicate that position 17 in the Shiga toxin/SLT-I B
subunit (which corresponds to position 16 in the SLT-IIrelated toxins) is involved in toxin-receptor binding. The
SLT-II-related toxins, SLT-Ilvha, SLT-Ilvhb, and SLT-IIc,
contain an uncharged asparagine residue at position 16,
whereas Shiga/SLT-I and SLT-II have a negatively charged
aspartic acid residue at this location. The lack of a negatively
charged amino acid at position 16 in the SLT-II-related toxins
may affect the electrostatic interaction between the amino
acids in the putative toxin-receptor binding cleft and result in
the observed reduction in toxin-receptor binding. Additional
studies which indicate that this region of the B subunit is
important in receptor binding include those of Tyrell et al.
(55). These investigators found that a D18N mutation in the B
subunit of SLT-I resulted in binding of the mutant toxin to Gb4
as well as to the functional receptor Gb3. It should be noted
that Ito et al. also demonstrated an antigenic dissimilarity
between SLT-II (VT2) and SLT-Ilvha (VT2vh) (13). However,
in contrast to our findings, these investigators attributed the
antigenic dissimilarity (which they observed by Ouchterlony
double-gel diffusion analysis) between the two toxins to the
alanine residue at position 24 in the B subunit of SLT-Ilvha
(13).
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Several explanations are possible for the disparity we observed between the in vitro cytotoxic activity of SLT-II-related
toxins and the activity of the toxins in animals. One possible
reason for the apparent relative inactivity of the SLT-II-related
toxins on Vero cells is the decreased affinity of these toxins for
the SLT-II functional receptor, Gb3 (Fig. 3). However, SLT-I
and SLT-II also differ in binding affinity for Gb3 but do not
exhibit differences in specific activity on Vero cells (51). An
alternative reason for the reduced toxicity of SLT-II-related
toxins on Vero cells is that the functional receptor that leads
from binding to internalization of these toxins is not Gb3 but
another receptor that is present at low levels on our Vero cells.
A corollary might be that the SLT-II-related toxins do bind
Gb3 on Vero cells but are not internalized efficiently. Whatever
the explanation for these in vitro findings, the toxicity of
SLT-II-related toxins is unimpaired in animals.
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